Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Cephalon, Inc.

Home Clinical Trial Sponsors and OrganizationsCephalon, Inc.

Cephalon, Inc.

ACTIVE

1090 Horsham Rd, North Wales, Pennsylvania, United Stateswww.cephalon.comSubsidiary3,726 employeesEstablished: 1987-01-01

Part of Teva Pharmaceutical Industries Ltd.

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

47

39 active

Approvals

4

Total approvals

Agencies

1

Regulatory bodies

Founded

1987

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

16

34.0%

Phase 3

3

6.4%

Phase 2

2

4.3%

Not Applicable

1

2.1%

Trial Status Distribution

Active, not recruiting

39

83.0%

Completed

2

4.3%

Terminated

5

10.6%

Clinical Trials

Trials sponsored by this organization (47)

A clinical study in children and adolescents with Excessive Sleepiness Associated With Narcolepsy to assess Pharmacokinetics, Pharmacodynamics, and Safety of Armodafinil (experimental drug).

Active, not recruiting

Mar 201345 participants

The purpose of this study is to look at the safety, effectiveness, and tolerability of armodafinil when used with mood stabilizers in subjects with major depression associated with bipolar I disorder.

Active, not recruiting

Apr 2012370 participants

AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF RESLIZUMAB (3.0 mg/kg) AS TREATMENT FOR PATIENTS WITH EOSINOPHILIC ASTHMA WHO COMPLETED A PRIOR CEPHALON-SPONSORED STUDY IN EOSINOPHILIC ASTHMA

Apr 201255 participants

The purpose of this study is to look at the safety, effectiveness, and tolerability of armodafinil when used with mood stabilizers in subjects with major depression associated with bipolar I disorder.

Active, not recruiting

Mar 2012370 participants

The purpose of this study is to look at the safety, effectiveness, and tolerability of armodafinil when used for 6 months with mood stabilizers in subjects with major depression associated with bipolar I disorder

Active, not recruiting

Sep 2011370 participants

The purpose of this study is to look at the safety, effectiveness, and tolerability of armodafinil when used for 6 months with mood stabilizers in subjects with major depression associated with bipolar I disorder

Active, not recruiting

Jun 2011370 participants

The purpose of this study is to look at the safety, effectiveness, and tolerability of armodafinil when used for 6 months with mood stabilizers in subjects with major depression associated with bipolar I disorder

Active, not recruiting

Jun 2011370 participants

The purpose of this study is to look at the safety, effectiveness, and tolerability of armodafinil when used with mood stabilizers in subjects with major depression associated with bipolar I disorder.

Active, not recruiting

Jun 2011370 participants

Page 1 of 6

Approvals

Approvals by Agency

FDA

Food and Drug Administration

4

Approvals

Recent Approvals

News

No news articles found

On this page

Overview
Clinical Trials47
Approvals4
News

Back to Organizations